Form 4 · Filed Jun 24, 2026, 10:05 PM UTC
BBIO/BridgeBio Pharma, Inc.
Dachille Douglas A. — director
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
2 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | A | other | 3,990 | $0 | — | 10,579 |
| Jun 22, 2026 | A | other | 5,277 | — | — | 5,277 |
Source: SEC EDGAR raw filing ↗ · Accession 0001470831-26-000626